Stock AnalizMirum Pharmaceuticals, Inc. MIRM
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Mirum Pharmaceuticals, Inc. (MIRM) is a healthcare company listed in the US with a market value of about $6.1B. In the twelve months to September 30, 2026 it had revenue of $671M and net income of -$904M, a net margin of -134.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $671M | $521M | $337M | $186M | $77M | $19M | $0 | — |
| Net income | -$904M | -$23M | -$88M | -$163M | -$136M | -$84M | -$103M | -$53M |
| Free cash flow | -$274M | $55M | $9M | -$71M | -$120M | -$133M | -$89M | -$40M |
| EPS (diluted) | $-15.48 | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 | $-4.58 |
| Net margin | -134.8% | -4.5% | -26.1% | -87.7% | -176.0% | -438.8% | — | — |
| ROIC | — | -5.4% | -29.4% | -34.4% | -86.9% | -111.5% | -47.0% | -32.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $157.71, 68% above the current price; targets range from $118.00 to $202.28; the consensus rating is “Strong buy”; expected EPS is $-15.67 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Mirum Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Mirum Pharmaceuticals pay a dividend?
Not currently.
Is Mirum Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Mirum Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.